

ASX RELEASE

Volpara Appoints Resident Radiology Expert Dr Monica Saini

Wellington, NZ, 19 September 2017: [Volpara Health Technologies](#) ("Volpara"; ASX: VHT), a digital health company focused on early detection of breast cancer by improving quality of screening, is pleased to announce the appointment of breast imaging physician Dr Monica Saini as Consultant Diagnostic Radiologist.

Dr Saini has dedicated her career to advancing the early detection of breast cancer. She worked as Chief of Breast Imaging at Santa Fe Imaging for eight years before becoming Consultant Medical Director of Automated Breast Ultrasound Systems (ABUS) for GE Healthcare. Dr Saini received her fellowship in Women's Imaging from the University of Washington School of Medicine. In addition to her medical doctorate, she holds a nursing degree.

"Each day, physicians face challenges in delivering the best care to their patients. Volpara's passionate team of experts is examining these obstacles and creating solutions. I am excited to work with Volpara to help patients and their providers," said Dr Saini. In addition to her work with Volpara, Dr Saini will be practicing radiology at Hutt Hospital in Wellington.

Volpara CEO Dr Ralph Highnam says Dr Saini brings a deep understanding of breast imaging diagnostics. Her knowledge and research will assist Volpara with further development of radiology products. Additionally, she has experience in surgery and oncology—two areas that represent significant commercial opportunities for Volpara.

"Dr Saini is an internationally recognised expert in a wide range of areas, but particularly on the issue of dense breast tissue and how to assess risk, and how to best image women to ensure their cancers are detected as early as possible," he said.

"She will work with Volpara to help us realise Volpara's full value not just in radiology but also across the surgery and oncology markets, substantially increasing our addressable market. We're very much looking forward to having her energy, enthusiasm and knowledge easily accessible to us once she moves to Wellington later this year."

ENDS.

About Volpara Health Technologies Limited (ASX: VHT)

Founded in 2009 from research originally conducted at Oxford University and based in Wellington, New Zealand, VHT facilitates the early detection of breast cancer through its digital health solutions to enable personalised, high-quality breast cancer screening based on automated, objective measurements of breast density and quality.

VHT has a number of patents and trademarks and regulatory clearances, including FDA and CE, supporting its technology and services.

An ASX-listed company that raised A\$20M through an IPO and subsequent share placement in 2016, VHT has customers and/or research projects in 36 countries.

www.volparasolutions.com

For further information, please contact:

Ralph Highnam, CEO
Volpara Health Technologies
ralph.highnam@volparasolutions.com
t: +64 21 149 0541

Kyahn Williamson
WE Buchan
kwilliamson@buchanwe.com.au
t: +61 3 9866 4722